Literature DB >> 22114048

Lymphocytic colitis secondary to ipilimumab treatment.

Alejandro García-Varona, Robert D Odze, Frederick Makrauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 22114048     DOI： 10.1002/ibd.22846

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  10 in total

1.  Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.

Authors:  Andrew P Wright; Marc S Piper; Shrinivas Bishu; Ryan W Stidham
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

2.  Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.

Authors:  Jagpal S Klair; Mohit Girotra; Laura F Hutchins; Kari D Caradine; Farshad Aduli; Mauricio Garcia-Saenz-de-Sicilia
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

Review 3.  Tipping the balance: inhibitory checkpoints in intestinal homeostasis.

Authors:  Maria E Joosse; Iris Nederlof; Lucy S K Walker; Janneke N Samsom
Journal:  Mucosal Immunol       Date:  2018-11-29       Impact factor: 7.313

Review 4.  The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.

Authors:  Ryosuke Yamauchi; Toshihiro Araki; Keiichi Mitsuyama; Takaaki Tokito; Hidenobu Ishii; Shinichiro Yoshioka; Kotaro Kuwaki; Atsushi Mori; Tetsuhiro Yoshimura; Osamu Tsuruta; Takuji Torimura
Journal:  BMC Gastroenterol       Date:  2018-08-31       Impact factor: 3.067

Review 5.  Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities.

Authors:  Stergios Boussios; Matin Sheriff; Elie Rassy; Michele Moschetta; Eleftherios P Samartzis; Rachel Hallit; Agne Sadauskaite; Konstantinos H Katsanos; Dimitrios K Christodoulou; Nicholas Pavlidis
Journal:  Ann Transl Med       Date:  2021-03

Review 6.  Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.

Authors:  Liansha Tang; Jialing Wang; Nan Lin; Yuwen Zhou; Wenbo He; Jiyan Liu; Xuelei Ma
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

Review 7.  Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists.

Authors:  Rachele Del Sordo; Umberto Volta; Vassilios Lougaris; Paola Parente; Angelo Sidoni; Mattia Facchetti; Gabrio Bassotti; Illuminato Carosi; Celeste Clemente; Vincenzo Villanacci
Journal:  Diagnostics (Basel)       Date:  2022-02-03

8.  Secukinumab-Induced Lymphocytic Colitis.

Authors:  Siva Santosh Kumar Gandu; Mohammad Hassaan Khan; Anush Vasikaran; Sudha Pandit
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

Review 9.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775

10.  Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.

Authors:  Carlos Eduardo de Andrea; Jose Luis Perez-Gracia; Eduardo Castanon; Mariano Ponz-Sarvise; Jose I Echeveste; Ignacio Melero; Miguel F Sanmamed; Maria Esperanza Rodriguez-Ruiz
Journal:  Oncoimmunology       Date:  2020-05-13       Impact factor: 8.110
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.